quinacrine and erlotinib hydrochloride

quinacrine has been researched along with erlotinib hydrochloride in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
De, S; Dermawan, JK; Dowlati, A; Gurova, K; Narla, G; Pink, J; Sharma, N; Stark, GR	1
Bhateja, P; Dowlati, A; Sharma, N	1
Gupta, V; Kulkarni, NS; Vaidya, B	1

Trials

1 trial(s) available for quinacrine and erlotinib hydrochloride

Article	Year
Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancer. Investigational new drugs, 2018, Volume: 36, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinacrine	2018

Article

Year

Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancer.

Investigational new drugs, 2018, Volume: 36, Issue:3

Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinacrine

2018

Other Studies

2 other study(ies) available for quinacrine and erlotinib hydrochloride

Article	Year
Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-κB, and cell-cycle progression in non-small cell lung cancer. Molecular cancer therapeutics, 2014, Volume: 13, Issue:9 Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA; DNA-Binding Proteins; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; High Mobility Group Proteins; Humans; Luciferases; Lung Neoplasms; Mice; Mice, Nude; NF-kappa B p50 Subunit; Quinacrine; Quinazolines; RNA, Small Interfering; Transcriptional Elongation Factors; Xenograft Model Antitumor Assays	2014
Nano-synergistic combination of Erlotinib and Quinacrine for non-small cell lung cancer (NSCLC) therapeutics - Evaluation in biologically relevant in-vitro models. Materials science & engineering. C, Materials for biological applications, 2021, Volume: 121 Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinacrine	2021

Article

Year

Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-κB, and cell-cycle progression in non-small cell lung cancer.

Molecular cancer therapeutics, 2014, Volume: 13, Issue:9

Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA; DNA-Binding Proteins; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; High Mobility Group Proteins; Humans; Luciferases; Lung Neoplasms; Mice; Mice, Nude; NF-kappa B p50 Subunit; Quinacrine; Quinazolines; RNA, Small Interfering; Transcriptional Elongation Factors; Xenograft Model Antitumor Assays

2014

Nano-synergistic combination of Erlotinib and Quinacrine for non-small cell lung cancer (NSCLC) therapeutics - Evaluation in biologically relevant in-vitro models.

Materials science & engineering. C, Materials for biological applications, 2021, Volume: 121

Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinacrine

2021